Alignment Healthcare, Inc. (NASDAQ:ALHC – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $23.60.
ALHC has been the topic of several research reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Alignment Healthcare in a research note on Tuesday, August 4th. TD Cowen reaffirmed a “buy” rating on shares of Alignment Healthcare in a research note on Monday, August 3rd. JPMorgan Chase & Co. cut their price objective on shares of Alignment Healthcare from $26.00 to $22.00 and set an “overweight” rating for the company in a report on Tuesday, August 4th. KeyCorp restated an “overweight” rating on shares of Alignment Healthcare in a report on Wednesday, June 10th. Finally, Zacks Research cut Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th.
View Our Latest Research Report on ALHC
Alignment Healthcare News Summary
- Neutral Sentiment: An AAII report discussed why Alignment Healthcare stock had risen, but the available headline provides no specific new fundamental catalyst, such as improved earnings guidance or a business announcement. Why Alignment Healthcare Stock Is Up
- Neutral Sentiment: Reported August short-interest data showed zero shares and a zero-day days-to-cover ratio, an internally inconsistent result that is unlikely to provide a meaningful signal for ALHC investors. Alignment Healthcare Short Interest Report
- Negative Sentiment: Kaplan Fox announced multiple investigations into Alignment Healthcare, its officers and directors, and potential violations of federal securities laws. The firm is seeking investors who suffered losses or have relevant information, raising the possibility of future shareholder claims. These are investigations and do not establish wrongdoing. Kaplan Fox Investigation
- Negative Sentiment: Lowey Dannenberg separately said it is investigating potential federal securities-law violations involving ALHC. The second law-firm inquiry reinforces near-term litigation uncertainty and could weigh on investor sentiment. Lowey Dannenberg Investigation
- Negative Sentiment: Kaplan Fox also urged Alignment Healthcare investors to contact the firm regarding a possible securities claim, repeating the investigation-related overhang across several releases. Kaplan Fox Possible Securities Claim
Insider Activity
In other news, insider Mark D. Kent purchased 14,848 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were purchased at an average price of $13.31 per share, with a total value of $197,626.88. Following the transaction, the insider owned 14,848 shares in the company, valued at $197,626.88. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John E. Kao sold 298,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $13.88, for a total transaction of $4,136,240.00. Following the completion of the sale, the chief executive officer directly owned 790,766 shares of the company’s stock, valued at $10,975,832.08. This represents a 27.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,009,951 shares of company stock valued at $18,597,287 in the last 90 days. 5.20% of the stock is owned by insiders.
Hedge Funds Weigh In On Alignment Healthcare
Several institutional investors and hedge funds have recently bought and sold shares of the company. Royal Bank of Canada lifted its stake in Alignment Healthcare by 92.6% during the first quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock worth $1,720,000 after purchasing an additional 44,413 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Alignment Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock worth $1,109,000 after buying an additional 2,594 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Alignment Healthcare by 79.1% during the first quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock worth $18,112,000 after buying an additional 429,703 shares during the period. Woodline Partners LP acquired a new position in Alignment Healthcare during the first quarter worth approximately $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Alignment Healthcare by 16.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock valued at $5,729,000 after buying an additional 44,452 shares during the last quarter. 86.19% of the stock is currently owned by institutional investors and hedge funds.
Alignment Healthcare Stock Up 2.3%
Alignment Healthcare stock opened at $13.90 on Friday. The business’s 50-day moving average price is $18.42 and its 200 day moving average price is $18.63. The company has a quick ratio of 1.70, a current ratio of 1.70 and a debt-to-equity ratio of 1.22. The firm has a market cap of $2.88 billion, a price-to-earnings ratio of 73.16 and a beta of 1.10. Alignment Healthcare has a 52 week low of $12.70 and a 52 week high of $25.12.
Alignment Healthcare (NASDAQ:ALHC – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. Alignment Healthcare had a return on equity of 20.02% and a net margin of 0.89%.The company had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same period in the previous year, the company posted $0.07 earnings per share. Alignment Healthcare’s revenue for the quarter was up 31.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Alignment Healthcare will post 0.17 earnings per share for the current year.
Alignment Healthcare Company Profile
Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.
At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.
Featured Articles
- Five stocks we like better than Alignment Healthcare
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Alignment Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alignment Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
